NSE ScannerChemicals · Chemicals: Specialty · NSE: TATVA · data 2026-11-01
Tatva Chintan Pharma Chem Limited
In plain words
Price: 22.2% below its 52-week high of ₹2,113.6.
Delivery: 37.2% of traded shares were kept for delivery over the last 10 sessions, against 43.9% over the last 60.
Latest results: a net profit of ₹21 cr for the quarter ended Sept 2026 (+116.2% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹650 cr |
| Net profit (last 12 months) | ₹63 cr |
| Sales growth, 3 years (yearly) | 6.0% |
| Profit growth, 3 years (yearly) | -2.6% |
At a glance
Promoters 72.0% (unchanged in a year), pledged 0.0%, institutions 7.6%.
P/E 61.1, P/B 4.7, dividend yield 0.1%. Price relative to earnings and book value (low is cheaper, not better).
ROE 5.5%, ROCE 7.9%, operating margin 13.3%: how much profit it earns on the money it uses.
Debt/equity 0.15, Profit growth -2.6% and sales growth 6.0% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (5.5%).
- Profit fell 2.6% a year over 3 years.
- Expensive on earnings (P/E 61.1).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
TATVA Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹217.32 crore, up 75.9% YoY and up 30.1% QoQ.
Net profit was ₹21.45 crore, up 116.2% YoY and up 34.2% QoQ.
Operating margin was 18.7% (18% a year ago).
EPS was ₹9.17, up 116.3% YoY and up 34.3% QoQ.
TATVA के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹217.32 करोड़; पिछले साल की तुलना में 75.9% की बढ़त, पिछली तिमाही की तुलना में 30.1% की बढ़त।
शुद्ध मुनाफ़ा: ₹21.45 करोड़; पिछले साल की तुलना में 116.2% की बढ़त, पिछली तिमाही की तुलना में 34.2% की बढ़त।
ऑपरेटिंग मार्जिन: 18.7% (एक साल पहले 18%)।
EPS: ₹9.17; पिछले साल की तुलना में 116.3% की बढ़त, पिछली तिमाही की तुलना में 34.3% की बढ़त।
TATVAના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹217.32 કરોડ; ગયા વર્ષની સરખામણીએ 75.9% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 30.1% વધારો.
ચોખ્ખો નફો: ₹21.45 કરોડ; ગયા વર્ષની સરખામણીએ 116.2% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 34.2% વધારો.
ઓપરેટિંગ માર્જિન: 18.7% (એક વર્ષ પહેલાં 18%).
EPS: ₹9.17; ગયા વર્ષની સરખામણીએ 116.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 34.3% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
17/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 9/30: Delivery 34.2% over the last 20 sessions vs 43.8% in the 40 before (0.78x); shares delivered per day 1.97x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 3/15: 1 scheme hold it, about ₹92 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 19 Oct 26Results Q2 FY27 results: profit +116.2% YoY -2.8% next session
- 11 Sept 26Dividend Dividend ₹2 (ex-date) -6.7% next session
- 17 Jul 26Results Q1 FY27 results: profit +140.3% YoY +20.8% next session
- 16 May 26Results Q4 FY26 results: profit +901.9% YoY -4.9% next session
- 21 Jan 26Results Q3 FY26 results: profit +10728.6% YoY -7.3% next session
- 31 Oct 25Results Q2 FY26 results: turned to profit vs a year ago +3.9% next session
- 12 Sept 25Dividend Dividend ₹1 (ex-date) +5.2% next session
- 24 Jul 25Results Q1 FY26 results: profit +27.6% YoY +14.9% next session
- 2 May 25Results Q4 FY25 results: profit −89.3% YoY 0.0% next session
- 29 Jan 25Results Q3 FY25 results: profit −96.0% YoY -4.0% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹217 cr | ₹21 cr | +116.2% | 18.7% | 9.17 |
| Jun 2026 | ₹167 cr | ₹16 cr | +140.3% | 19.3% | 6.83 |
| Mar 2026 | ₹134 cr | ₹10 cr | +901.9% | 21.0% | 4.41 |
| Dec 2025 | ₹131 cr | ₹15 cr | +10728.6% | 19.4% | 6.49 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 72.02% | 72.02% | 72.02% | 72.02% |
| Foreign institutions (FII) | 4.38% | 3.93% | 3.82% | 4.17% |
| Domestic institutions (DII) | 3.21% | 3.11% | 2.99% | 3.33% |
| Mutual funds | 2.87% | 2.79% | 2.87% | 3.25% |
| Retail investors | 14.07% | 14.26% | 14.36% | 13.82% |
| Number of shareholders | 62,888 | 64,921 | 66,842 | 68,657 |
Common questions
What was Tatva Chintan Pharma Chem Limited's latest quarterly profit?
Tatva Chintan Pharma Chem Limited reported a net profit of ₹21 cr for the quarter ended Sept 2026 (+116.2% on the same quarter a year earlier), on revenue of ₹217 cr.
How much do promoters hold in Tatva Chintan Pharma Chem Limited?
Promoters held 72.02% of Tatva Chintan Pharma Chem Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Tatva Chintan Pharma Chem Limited debt-free?
Its latest reported debt-to-equity ratio is 0.15.
What is Tatva Chintan Pharma Chem Limited's P/E ratio?
About 61.1, based on the last 12 months' earnings and a price of ₹1,643.9 (data 2026-11-01).
What is the 52-week high and low of Tatva Chintan Pharma Chem Limited?
The 52-week high is ₹2,113.6 and the 52-week low is ₹1,044.1.
Mutual funds holding Tatva Chintan Pharma Chem Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 1 scheme holding about ₹92 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| Nippon India ELSS Tax Saver Fund | Nippon India Mutual Fund | 0.65% | ₹92 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Tatva Chintan Pharma Chem Limited | ₹1,643.9 | ₹3,849 cr | 61.1 | 4.7 | 5.5% | 7.9% | 0.15 | +20.4% |
| Gujarat Alkalies & Chemicals Ltd. | ₹541.2 | ₹3,971 cr | 59.9 | — | 0% | -0.5% | 0.11 | -6.3% |
| Steamhouse India Limited | ₹132.24 | ₹3,667 cr | — | 6.3 | 25.3% | 22% | 1.94 | +39.9% |
| Vishnu Chemicals Limited | ₹542.15 | ₹3,648 cr | 24.4 | — | 14.3% | 16.2% | 0.49 | +11.3% |
| Grauer & Weil India Ltd. | ₹80.28 | ₹3,637 cr | 22.7 | — | 16.2% | 16.4% | 0.01 | +33.7% |
| Kiri Industries Limited | ₹539.1 | ₹3,517 cr | 0.6 | — | 115% | -2.6% | 0.01 | -4.3% |
Compare TATVA with GUJALKALI in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open TATVA in NSE Scanner →